




The relative strengths and weaknesses of Immunome Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immunome Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 64% points. The greatest weakness of Immunome Inc is the variable Net Income, reducing the Economic Capital Ratio by 75% points.

The company's Economic Capital Ratio, given in the ranking table, is 204%, being 11% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	221,339
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	54,307
Liabilities, Non-Current	4,769
Other Assets	8,789
Other Compr. Net Income	35
Other Expenses	152,344
Other Liabilities	0
Other Net Income	12,837
Other Revenues	9,041
Property and Equipment	10,113
Research and Development	129,542
Selling, General and Administrative Expense	32,955

Output Variable	Value in 1000 USD
Assets	240,241
Liabilities	59,076
Expenses	314,841
Revenues	9,041
Stockholders Equity	181,165
Net Income	-292,963
Comprehensive Net Income	-292,946
BaseVar	318,036
ECR before Limited Liability	68%
Economic Capital Ratio	204%